SABCS 2024 | DECRESCENDO: de-escalating chemotherapy in HER+, HR- early breast cancer
Elisa Agostinetto, MD, Jules Bordet Institute, Brussels, Belgium, discusses findings from the Phase II DECRESCENDO trial (NCT04675827) of anthracycline-free treatment for HER2-positive, HR-negative, node-negative early breast cancer. Patients received neoadjuvant taxane-based therapy with pertuzumab and trastuzumab, achieving a high pathologic complete response. Although terminated early due to slow recruitment, the study demonstrates the potential of de-escalated regimens to maintain efficacy while minimizing long-term chemotherapy-related toxicity. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
